Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-20), abrdn Life Sciences Investors's 3-1 Month Momentum % is 13.38%.
The industry rank for abrdn Life Sciences Investors's 3-1 Month Momentum % or its related term are showing as below:
HQL's 3-1 Month Momentum % is ranked better than 89.88% of 1630
companies
in the Asset Management industry
Industry Median: 0.68
vs HQL: 13.38
abrdn Life Sciences Investors (NYSE:HQL) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
abrdn Life Sciences Investors 3-1 Month Momentum % Related Terms
HQL vs IIM, NOAH, FAX: 3-1 Month Momentum % Comparison
For the Asset Management subindustry, abrdn Life Sciences Investors's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors 3-1 Month Momentum % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's 3-1 Month Momentum % falls into.
abrdn Life Sciences Investors (NYSE:HQL) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (HQL) has a 3-1 Month Momentum % of 13.38% as of Aug. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on abrdn Life Sciences Investors and its competitors. According to the industry distribution chart, abrdn Life Sciences Investors ranks #165 out of 1630 companies in the Asset Management industry, placing it in the top 10.1%.
Is abrdn Life Sciences Investors' 3-1 Month Momentum % too high?
abrdn Life Sciences Investors' current 3-1 Month Momentum % is 13.38%. The Asset Management industry median 3-1 Month Momentum % is 0.68. abrdn Life Sciences Investors' value of 13.38% is 1867.6% above this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #165 out of 1630 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' 3-1 Month Momentum % compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #165 out of 1630 companies for 3-1 Month Momentum %. This places abrdn Life Sciences Investors in the top 10% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.68. abrdn Life Sciences Investors' value of 13.38% is 1867.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for an Asset Management company?
The median 3-1 Month Momentum % among Asset Management companies is 0.68, based on 1,630 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current 3-1 Month Momentum % of 13.38% is 1867.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median 3-1 Month Momentum % is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current 3-1 Month Momentum % is 13.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.29 — trading 64.1% below its estimated fair value. The current 3-1 Month Momentum % is 13.38% and 1867.6% above the Asset Management industry median of 0.68. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current 3-1 Month Momentum % is 13.38% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $22.29 is trading 64.1% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
3-1 Month Momentum %: 13.38%
GF Value™: $62.01 vs. price of $22.29 (64.1% below fair value)
Industry Position: 1867.6% above the Asset Management median (#165 of 1630)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
